Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | == | + | ==Mechanism of action== |
| + | Anti-CD22 antibody | ||
| + | |||
| + | ==Preliminary data== | ||
| + | ===[[Acute lymphocytic leukemia]]=== | ||
# Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] | # Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Chemotherapy]] |
| + | [[Category:Intravenous chemotherapy]] | ||
| + | |||
| + | [[Category:Immunotherapy]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Acute lymphocytic leukemia medications]] | [[Category:Acute lymphocytic leukemia medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 01:51, 26 November 2014
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. link to original article